Join
Live feed
·
PRReleasevia Quantisnow
Maze Therapeutics Inc. logo

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

ByQuantisnow·Wall Street's wire, on your screen.
MAZE· Maze Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MAZE (Maze Therapeutics Inc.) and more on Quantisnow.